Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic pulmonary fibrosis

Tweetable abstract

Consistent with prior observational studies, pirfenidone and nintedanib were observed to have reduced risk of mortality and hospitalisations in patients with IPF in this large US Medicare dataset. The result holds after accounting for “immortal time bias”.https://bit.ly/3YWFyTK